Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
종목 코드 ALMR
회사 이름Alamar Biosciences Inc
상장일Apr 17, 2026
CEOLuo (Yuling)
직원 수- -
유형Ordinary Share
회계 연도 종료- -
주소47071 Bayside Pkwy
도시FREMONT
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94538
전화15106269888
웹사이트https://alamarbio.com
종목 코드 ALMR
상장일Apr 17, 2026
CEOLuo (Yuling)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음